Results 71 to 80 of about 42,616 (245)

Protective role of the alpha-1-antitrypsin in intervertebral disc degeneration

open access: yesJournal of Orthopaedic Surgery and Research, 2021
Background Intervertebral disc degeneration is a complex disease with high prevalence. It suggests that cell death, senescence, and extracellular matrix degradation are involved in the pathogenesis. Alpha-1 antitrypsin (AAT), a serine protease inhibitor,
Weikun Liu, Yanfu Wang
doaj   +1 more source

Mass Spectrometry Structural Proteomics Enabled by Limited Proteolysis and Cross‐Linking

open access: yesMass Spectrometry Reviews, EarlyView.
ABSTRACT The exploration of protein structure and function stands at the forefront of life science and represents an ever‐expanding focus in the development of proteomics. As mass spectrometry (MS) offers readout of protein conformational changes at both the protein and peptide levels, MS‐based structural proteomics is making significant strides in the
Haiyan Lu   +4 more
wiley   +1 more source

Diagnosis of alpha-1-antitrypsin deficiency by DNA analysis of children with liver disease

open access: yesArquivos de Gastroenterologia, 2001
Background - Alpha-1-antitrypsin deficiency is a genetic disorder which is transmitted in a co-dominant, autosomal form. Alpha-1-antitrypsin deficiency affects mainly the lungs and the liver leading, in the latter case, to neonatal cholestasis, chronic ...
De TOMMASO Adriana Maria Alves   +5 more
doaj  

All-atom simulations reveal how single point mutations promote serpin misfolding

open access: yes, 2018
Protein misfolding is implicated in many diseases, including the serpinopathies. For the canonical inhibitory serpin {\alpha}1-antitrypsin (A1AT), mutations can result in protein deficiencies leading to lung disease, and misfolded mutants can accumulate ...
Beccara, Silvio a   +7 more
core   +1 more source

Management of chronic airway diseases:What can we learn from real-life data? [PDF]

open access: yes, 2017
Chronic obstructive pulmonary disease (COPD), alpha-1 antitrypsin deficiency (AATD) and non-cystic fibrosis bronchiectasis (hereafter referred to as bronchiectasis) are distinct but related airway diseases: COPD is characterised by persistent and usually
Greulich T, James D. Chalmers
core   +3 more sources

The Plasma Free Fatty Acid Carrier Proteome is Altered in Diet‐Induced and Genetically Obese Mice

open access: yesObesity, EarlyView.
ABSTRACT Objective We aimed to examine the effect of obesity on the plasma free fatty acid (FFA) carrier proteome in mice. Methods From 6 to 20 weeks of age, male and female C57BL/6J wild‐type mice were fed either a low‐fat diet (10% of kilocalories from fat) or a high‐fat diet (60% of kilocalories from fat), and leptin‐deficient ob/ob mice were fed a ...
Keigo Tomoo   +3 more
wiley   +1 more source

Comparative evaluation of serum alpha-1antitrypsin levels in patients with oral squamous cell carcinoma and in subjects with tobacco habit without carcinoma

open access: yesJournal of Family Medicine and Primary Care, 2019
Aim/Objectives: To evaluate serum levels of Alpha-1 antitrypsin in patients with oral squamous cell carcinoma and compare them with that of healthy subjects with and without tobacco habits. Materials and Method: The sample of 83 subjects was divided into
Upasana S Ahuja   +5 more
doaj   +1 more source

CemOrange2 fusions facilitate multifluorophore subcellular imaging in C. elegans [PDF]

open access: yes, 2019
Due to its ease of genetic manipulation and transparency, Caenorhabditis elegans (C. elegans) has become a preferred model system to study gene function by microscopy.
Buland, Justin R   +14 more
core   +3 more sources

Novel Therapeutics for Chronic Obstructive Pulmonary Disease: From Empirical Bronchodilation to Precision Medicine

open access: yesRespirology, EarlyView.
ABSTRACT Chronic obstructive pulmonary disease (COPD) remains the third leading cause of death worldwide, and conventional bronchodilator‐based therapies have limited efficacy in preventing exacerbations and disease progression. The 2024–2026 period represents a historic inflection point: three mechanistically distinct agents received Food and Drug ...
Naoya Fujino, Hisatoshi Sugiura
wiley   +1 more source

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
We conducted a nationwide, multicenter cohort study using a target trial emulation framework to compare baclofen and acamprosate in patients with compensated alcohol‐associated cirrhosis. After matching, baclofen initiation was associated with a higher 1‐year risk of major adverse liver outcomes, driven primarily by hepatic encephalopathy, particularly
Yee Hui Yeo   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy